Ex vivo nail infection as an effective preclinical method for screening of new topical antifungals - 26/02/20
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Highlights |
• | Ex vivo model allows to evaluate drugs or new molecules that combat onychomycosis. |
• | Ex vivo model is fundamental to analyze results previously obtained by in vitro models. |
• | Swine hoof was a suitable substitute for human nail plate. |
• | The method presented an infection condition close to a real situation. |
Abstract |
Onychomycosis are fungal nail infections comprising of about 50% of onychopathies and are commonly caused by dermatophytes. The treatment of this dermatomycosis requires a long period of time and is associated with high rates of recurrence. In view of the need to evaluate the antifungal performance of promising preclinical compounds, we developed, in this study, a practical and accessibleex vivo model for establishing a Trichophyton rubrum onychomycosis framework using porcine hooves. This model has as its main advantage the similar structural and three-dimensional characteristics that the porcine hooves have with the human nail. The proposed model allowed to evaluate the antifungal activity of a new antifungal compound and a reference drug (terbinafine), both already incorporated into a nail lacquer for topical use. Treatments with compound 3-selenocyanate-indole (Se4a) and with terbinafine incorporated into this nail lacquer completely inhibited fungal growth, corresponding to the profile of in vitro activity observed against T. rubrum. This study concludes that the ex vivo porcine hoof model is an effective alternative method for preclinical screening of drugs or new topical compounds developed to combat onychomycosis. Further studies are needed to compare the permeability of porcine hooves with human nails permeability.
Le texte complet de cet article est disponible en PDF.Keywords : Ex vivo, Antifungal, Onychomycosis, Porcine hooves, Nail infection
Abbreviation : Se4a
Plan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?